title: [Economic aspects of polyvalent immunoglobulins].
abstract: Immunoglobulins differ from other drugs in several respects. In particular, they are derived from human plasma, which theoretically limits their availability, and their cost is sufficiently high to place economic pressure on the healthcare system. This implies the need for tight regulation. Immunoglobulin prescription is gradually increasing in France, and all new indications must be thoroughly assessed in prospective studies.
authors.affiliation: Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, 27 rue du Faubourg Saint-Jacques, 75014 Paris. loic.guillevin@orange.fr
authors.forename: Loïc
authors.initials: L
authors.lastname: Guillevin
mesh_terms: D017048:Health Care Costs; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000191:economics* / Q000627:therapeutic use
chemical_list: D016756:Immunoglobulins, Intravenous